

08-06-01

Anticipated Classification  
of this Application:  
Class \_\_\_\_\_ Subclass \_\_\_\_\_

Prior Application:  
Examiner P. Gambel  
Group Art Unit 1644

Attorney's  
Docket  
No. 65019-DC-PCT-US/  
JPW/AJM/NFM

08/03/01

REMARKABLE ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

10971 U.S. PTO  
09/921937  
08/03/01

S I R:

This is a request for filing a X CONTINUATION

       DIVISIONAL        CONTINUATION-IN-PART application under

X 37 C.F.R. §1.53(b)        37 C.F.R. §1.53(d), of pending prior application

Serial No. 08/690,775 filed on August 1, 1996 of

Marc Feldmann and Ravinder N. Maini for  
inventor(s)

ANTI-TNF ANTIBODIES AND METHOTREXATE IN THE TREATMENT OF AUTOIMMUNE DISEASE

Title of Invention

X Enclosed is a copy of the prior application, as originally  
filed.

       A verified statement to establish small entity status under  
37 C.F.R. §1.9 and 1.27

       is enclosed.

       was filed in the prior application and such status  
is still proper and desired (37 C.F.R. §1.28(a)).

X The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED		NUMBER EXTRA*		RATE		FEE	
					SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	38_20	=	18	X	9	18	= \$	\$ 324
Independent Claims	4-3	=	1	X	40	80	= \$	\$ 80
Multiple Dependent Claims Presented: <u>      </u> Yes <u>X</u> No					135	270	= \$	\$
					BASIC FEE		\$ 690	\$ 710
					TOTAL FEE		\$	\$ 1,114

\*If the difference in Col. 1 is  
less than zero, enter "0" in  
Col. 2.

<sup>1</sup> Filing an application pursuant to this section expressly abandons the  
parent application.

Marc Feldmann & Raymond N. Maini  
Serial No.: Not yet known  
Filed: Herewith

Cont.Div.  
Page 2

4. X The Commissioner is hereby authorized to charge payment of the following fees associated with this application or credit any overpayment to Deposit Account No. 03-3125.
- X Any additional filing fees required under 37 C.F.R. §1.16.
- X Any patent application processing fees under 37 C.F.R. §1.17.
- The issue fees set forth in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).
5. X Three copies of this sheet are enclosed.
6. X A check in the amount of \$ 1,114.00 is enclosed.
7.        Cancel claims       .
8.        Amend the specification by inserting before the first line the sentence: --This is a        continuation        division of application Serial No.       , filed       ---
9. X 8 Sheet(s) of X informal        formal drawing(s) is/are enclosed.
10.        Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.
11.        Priority of application No.        filed on        in        (country) is claimed under 37 U.S.C. §119.
- The certified copy of the priority application has been filed in prior application Serial No.       , filed       .
12. X The prior application is assigned of record to The Kennedy Institute of Rheumatology.
13. X A preliminary amendment is enclosed.
14. X The power of attorney in the prior application is to:

John P. White (Reg. No. 28,678).

Marc Feldmann & Ravinder N. Maini  
Serial No.: Not yet known  
Filed: Herewith

Cont/Div.  
Page 3

- (a) \_\_\_\_\_ The power appears in the original papers in the prior application.
- (b) X Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- (c) X Address all future communications to:  
(May only be completed by applicant, or attorney or agent of record.)

John P. White

Cooper & Dunham LLP

1185 Avenue of the Americas

New York, New York 10036

15. X

Also enclosed Express Mail Certificate of Mailing No.

EJ470125269US Dated: August 3, 2001

16. X

I hereby verify that the attached papers are a true copy of prior application Serial No. 08/690,775 as originally filed on August 1, 1996.

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statement and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date

8/3/01

Signature

Alan J. Morrison  
Reg. No. 37,399

\_\_\_\_ INVENTOR(S)  
\_\_\_\_ ASSIGNEE OF COMPLETE INTEREST  
\_\_\_\_ ATTORNEY OR AGENT OF RECORD  
X FILED UNDER 37 C.F.R. §1.34(a)

Address of Signator:

Cooper & Dunham LLP

1185 Avenue of the Americas

New York, New York 10036

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Marc Feldmann, et al.

Serial No.: Not Yet Known

Filed: Herewith

For: ANTI-TNF ANTIBODIES AND METHOTREXATE IN THE  
TREATMENT OF TNF-MEDIATED DISEASE

1185 Avenue of the Americas  
New York, New York 10036  
August 3, 2001

Assistant Commissioner For Patents  
Washington, D.C. 20231

SIR:

**EXPRESS MAIL CERTIFICATE OF MAILING**  
**FOR ABOVE-IDENTIFIED APPLICATION**

"Express Mail" mailing label number: EJ470125269US  
Date of Deposit: August 3, 2001

I hereby certify that this paper or fee is being deposited to the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231:

Printed Name: THW 1920A

Respectfully submitted,

John P. White  
Registration No. 28,678  
Alan J. Morrison  
Registration No. 37,399  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
Tel. No. (212) 278-0400